3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
58
Neoplasm Metastasis
21
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Brain Neoplasms
8
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Neoplasms
3
Esophageal Neoplasms
3
Advanced Breast Cancer
3
Adenocarcinoma
3
Prostatic Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Gastric Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Solid Tumor
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Interventions
pembrolizumab
7
Nivolumab
7
Specimen Handling
6
Mitomycin
6
Magnetic Resonance Spectroscopy
6
Capecitabine
6
Radiotherapy
5
Fluorouracil
4
Drug Therapy
4
Biopsy
4
Radiation
3
Paclitaxel
3
Ipilimumab
3
Fluorodeoxyglucose F18
3
Carboplatin
3
dehydroftorafur
2
atezolizumab
2
aldesleukin
2
Tomography, X-Ray Computed
2
Sigmoidoscopy
2
Radiotherapy, Intensity-Modulated
2
Proctoscopy
2
Mitozytrex
2
Colonoscopy
2
CTLA-4 Antigen
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
spartalizumab
1
enzalutamide
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
trastuzumab deruxtecan
×
1 year
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled